M/S. Reata Pharmaceuticals v. Union Of India

Every founder dreams of the moment their breakthrough product earns a patent. But what happens when the patent office issues an unfavorable order, and the innovator decides to leapfrog the appeals process straight to the High Court? The case of M/S. Reata Pharmaceuticals versus the Union of India offers a sharp reminder: in IP disputes, choosing the wrong legal doorway can slam your case shut before the merits are ever heard. This story matters because it illustrates a foundational principle of patent litigation — the discipline of following the procedural path laid out by law.

M/S. Reata Pharmaceuticals, a company working on pharmaceutical innovation, found itself at odds with an order passed by the Controller of Patents. The petitioner believed that the Controller had failed to properly consider what they described as superior data relating to an improved version of their product. Convinced that the patent authority had overlooked critical evidence, Reata Pharmaceuticals chose to file a writ petition directly before the High Court, challenging the Controller's order and seeking relief against the Union of India and another respondent. The dispute centered on whether the patent authority had given due weight to the technical and scientific data Reata presented in support of its improved formulation.

Reata Pharmaceuticals argued that the Controller of Patents had erred by failing to consider the superior data they had submitted regarding their improved product version. From the petitioner's perspective, the patent authority's order was flawed because it did not properly evaluate the enhanced characteristics or benefits of the new formulation. On the other side, the respondents — the Union of India and the other party — countered that Reata had taken an impermissible shortcut. Their central argument was procedural: the petitioner had bypassed the statutorily prescribed remedy available to them. The legal friction was not really about the science of the improved product; it was about whether Reata had the right to invoke the writ jurisdiction of the High Court when a dedicated appellate mechanism already existed under the patent statute.

The court dismissed the writ petition. Its reasoning rested on a well-established principle of administrative and IP law: when an order is appealable under a statute, the aggrieved party must ordinarily pursue that statutory remedy rather than approach the High Court directly through a writ petition. The court held that the existence of a statutory alternative remedy is not an absolute bar to writ jurisdiction — but it becomes decisive unless the impugned order was passed without jurisdiction or was vitiated by a breach of the principles of natural justice. Since Reata did not establish either of those exceptional circumstances, the petition was dismissed, leaving the petitioner to pursue the appeal route provided by the patent law framework.

For founders, startup leaders, and IP professionals, the lesson is procedural but profound: always map out the full statutory appeal ladder before reaching for extraordinary remedies like writ petitions. A strong case on the merits can still be defeated by a weak choice of forum. If you believe a patent office has ignored your data or erred in its analysis, document your grievances carefully, but channel them through the designated appellate authority first. Reserve writ jurisdiction for situations where the lower authority truly lacked jurisdiction or violated natural justice — not as a convenient shortcut. Disciplined procedural strategy protects your substantive innovations from being lost on a technicality.